ALQGC Fundamental Analysis - QUANTUM GENOMICS SAS-REGR

Fundamental Rating

ALQGC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. ALQGC has a bad profitability rating. Also its financial health evaluation is rather negative. ALQGC has a valuation in line with the averages, but on the other hand it scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALQGC has reported negative net income.
ALQGC had negative earnings in each of the past 5 years.
In the past 5 years ALQGC always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -84.63%, ALQGC is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
With a Return On Equity value of -726.18%, ALQGC is not doing good in the industry: 75.71% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-84.63%
ROE	-726.18%
ROIC	N/A

ROA(3y)-87.78%

ROA(5y)-71.29%

ROE(3y)-517.57%

ROE(5y)-335.54%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALQGC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALQGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALQGC has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, ALQGC has a worse debt to assets ratio.

2.2 Solvency

ALQGC has an Altman-Z score of -11.61. This is a bad value and indicates that ALQGC is not financially healthy and even has some risk of bankruptcy.
ALQGC has a Altman-Z score of -11.61. This is amonst the worse of the industry: ALQGC underperforms 84.29% of its industry peers.
ALQGC has a Debt/Equity ratio of 4.49. This is a high value indicating a heavy dependency on external financing.
ALQGC's Debt to Equity ratio of 4.49 is on the low side compared to the rest of the industry. ALQGC is outperformed by 72.86% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	4.49
Debt/FCF	N/A
Altman-Z	-11.61

ROIC/WACCN/A

WACC7.48%

2.3 Liquidity

A Current Ratio of 2.73 indicates that ALQGC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.73, ALQGC is in line with its industry, outperforming 60.00% of the companies in the same industry.
A Quick Ratio of 2.73 indicates that ALQGC has no problem at all paying its short term obligations.
ALQGC has a Quick ratio of 2.73. This is comparable to the rest of the industry: ALQGC outperforms 60.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.73
Quick Ratio	2.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALQGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.28%, which is quite impressive.
The Revenue for ALQGC has decreased by -98.34% in the past year. This is quite bad
ALQGC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -79.70% yearly.

EPS 1Y (TTM)87.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.58%

Revenue 1Y (TTM)-98.34%

Revenue growth 3Y-79.7%

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y6121.43%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year1744.53%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALQGC. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 0.02, which indicates a rather cheap valuation of ALQGC.
Based on the Price/Forward Earnings ratio, ALQGC is valued cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ALQGC to the average of the S&P500 Index (24.31), we can say ALQGC is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.02

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALQGC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALQGC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

QUANTUM GENOMICS SAS-REGR

EPA:ALQGC (10/24/2024, 7:00:00 PM)

0.0721

0 (-1.77%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-22 2024-10-22

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap5.00M

Revenue(TTM)10.06K

Net Income(TTM)-3.17M

Analysts34.29

Price Target10.2 (14047.02%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.02
P/S	496.96
P/FCF	N/A
P/OCF	N/A
P/B	11.45
P/tB	11.45
EV/EBITDA	N/A

EPS(TTM)-0.09

EYN/A

EPS(NY)4.34

Fwd EY6021.43%

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0

BVpS0.01

TBVpS0.01

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-84.63%
ROE	-726.18%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-87.78%

ROA(5y)-71.29%

ROE(3y)-517.57%

ROE(5y)-335.54%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	4.49
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.73
Quick Ratio	2.73
Altman-Z	-11.61

F-ScoreN/A

WACC7.48%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)87.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.58%

EPS Next Y6121.43%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-98.34%

Revenue growth 3Y-79.7%

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year1744.53%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y89.57%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year3919.47%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

QUANTUM GENOMICS SAS-REGR / ALQGC.PA FAQ

What is the fundamental rating for ALQGC stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALQGC.PA.

What is the valuation status of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) stock?

ChartMill assigns a valuation rating of 4 / 10 to QUANTUM GENOMICS SAS-REGR (ALQGC.PA). This can be considered as Fairly Valued.

How profitable is QUANTUM GENOMICS SAS-REGR (ALQGC.PA) stock?

QUANTUM GENOMICS SAS-REGR (ALQGC.PA) has a profitability rating of 0 / 10.

Can you provide the financial health for ALQGC stock?

The financial health rating of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) is 3 / 10.

QUANTUM GENOMICS SAS-REGR (ALQGC.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

QUANTUM GENOMICS SAS-REGR / ALQGC.PA FAQ

What is the fundamental rating for ALQGC stock?

What is the valuation status of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) stock?

How profitable is QUANTUM GENOMICS SAS-REGR (ALQGC.PA) stock?

Can you provide the financial health for ALQGC stock?